Overview Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX Status: Recruiting Trial end date: 2022-07-30 Target enrollment: Participant gender: Summary A randomized, double-blind, Multicenter, parallel, placebo-controlled study Phase: Phase 3 Details Lead Sponsor: Yooyoung Pharmaceutical Co., Ltd.Yooyoung Pharmaceutical Co.,Ltd.